The Relative Strength Index (RSI) is a technical analysis indicator that provides information about whether a security can be classified as “overbought” or “oversold.” When looking at the RSI for Alkermes stock over the last seven days, the current value is that it does not fall into overbought or oversold territory. The stock is therefore given a “Neutral” rating. The RSI for the past 25 trading days also shows lower volatility compared to the RSI for the past seven days, adding a more long-term perspective. On this basis, Alkermes is also classified as neither overbought nor oversold with a value of 44.737 and therefore also receives a “neutral” rating for the RSI25. Overall, the analysis of the RSIs results in a consistent “Neutral” rating for Alkermes.
In terms of sentiment and buzz in internet communication, the analysis shows that sentiment for Alkermes has barely changed in recent weeks, resulting in a “Neutral” rating. However, discussion strength, a measure of investor attention on social media, shows decreasing activity over the past four weeks. This indicates that market participants have decreased interest in the share, which is why Alkermes is rated “Poor” from this perspective. Overall, the stock receives a “poor” rating in this category.
Fundamentally, Alkermes’ current price-to-earnings ratio (P/E) is 10.92, below the biotechnology industry average of 43.25. This undervaluation results in a “Good” rating based on fundamental criteria.
In the last two weeks, Alkermes has received positive reviews from mostly private users on social media. This assessment results from the evaluation of various comments that have dealt with the share during this period. In addition, predominantly positive topics surrounding the security have been discussed in the last few days. Given these factors, investor sentiment is rated as “Good”, resulting in an overall “Good” rating for the investor sentiment measurement.
Buy, hold or sell – your Alkermes analysis from September 30th. provides the answer:
How will Alkermes develop now? Is it worth getting started or should investors sell? You can find out the answers to these questions and why you need to act now in the current Alkermes analysis.
Alkermes: Buy or sell? Read more here…
